Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients
All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients
Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile
The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.
'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.'
'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.'
In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment.
Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing.
Clinical Development PlansIntellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit clinicaltrials.gov.
About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical ProgramIntellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit clinicaltrials.gov (NCT05120830) for more details. About Lonvo-zBased on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Intellia TherapeuticsIntellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.Investors:Brittany ChavesSenior Manager, Investor Relationsbrittany.chaves@intelliatx.com
Media:Matt CrensonTen Bridge Communicationsmcrenson@tenbridgecommunications.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
'Forever chemical' found in all but one of tested UK rivers
A chemical that scientists worry might have an impact on human reproduction has been found in rivers across the UK. Researchers from York University analysed samples from 32 rivers in all the UK's 4 nations and found traces of trifluoroacetic acid (TFA) at 98% of the test locations. TFA is what's known as a "forever chemical" which means that it breaks down extremely slowly in nature, and so accumulates over time. As with other "forever chemicals", also known as PFAS, just how much a threat to human health and at what concentrations is still being researched. But scientists in Germany say having looked at the impact of TFA on animals they want it to be classed as toxic for reproduction. TFA forms when synthetic chemicals from other "forever chemicals" such as those found in pesticides and refrigerants are partially broken down. "This molecule (TFA) is everywhere," Alistair Boxall, professor of Environmental Science at the University of York who carried out the research, told the BBC. "We will all be drinking water containing TFA every day - so we'll be exposed throughout our lifetime. It's that long-term, low level exposure that is the big concern." This new study was funded by environmental charity Fidras and involved sampling in 5 rivers in Wales, 3 in Northern Ireland 14 in Scotland and 10 in the north of England. The highest concentration was recorded on the River Kelvin in Glasgow. The River Ness, which flows from Loch Ness to the Moray Firth, was the only river sampled not to show traces of TFA. Recent studies in the EU have found TFA to be widespread, including in wine and food, human blood and breast milk. Authorities in Germany have been looking with interest at rising TFA levels in drinking water. In the last two decades its concentrations have gone up fourfold and researchers have been trying to establish what impact - if any - it might have on human health. Citing scientific studies that showed TFA affecting rabbit and rat foetuses, the German Federal Environment Agency (UBA) has applied to the European Chemicals Agency (ECHA) for TFA to be classified as toxic for reproduction and harmful to the environment. That could eventually lead to recommendations being made in the EU as to how products containing TFA should be controlled. "Currently, there are no expected adverse health effects from consuming water or food contaminated with TFA," said Andreas Hensel, president of the German Federal Institute for Risk Assessment (BfR). "The new classification is an important step in preparing further measures to ensure that this remains the case in the future". There aren't currently any rules or regulations in place to identify or reduce the concentrations of TFA either in the environment or in drinking water supplies in the UK. But aware of concerns, the Drinking Water Inspectorate, which monitors and regulates drinking water quality in England and Wales, has just commissioned its own research. It will look at how much TFA is already in drinking water and what risk - if any - it poses. "The information signposted by the University of York suggests that TFA can be formed from the degradation of PFAS-containing pesticides," Ann Bunting, Principal Inspector of the Drinking Water Inspectorate, told the BBC. "It is important that the fate of pesticides and other chemicals in the environment is understood, in order to protect drinking water sources." A spokesperson for Water UK, which represents the UK's water companies, told the BBC: "We want to see PFAS, including TFA, banned and the development of a national plan to remove it from the environment which should be paid for by manufacturers." Warning over 'dirty secret' of toxic chemicals on farmers' fields 'Forever chemicals' limited in US tap water Toughen 'forever chemical' water rules - experts
Yahoo
2 hours ago
- Yahoo
A new lens on regulation: The Modern Regulator launches to track the evolving landscape of regulation across Australia, New Zealand, the UK and beyond
SYDNEY, June 16, 2025 /PRNewswire/ -- The Modern Regulator is a new digital publication dedicated to examining the changing nature of regulation and the people, processes, and technologies shaping it. With a primary focus on Australia, New Zealand, and the United Kingdom, the publication offers nuanced, expert-driven coverage of regulatory issues while also tracking developments and best practices globally. Developed by a team with deep experience in regulation, public policy, journalism, and technology, The Modern Regulator was founded on a shared commitment to telling meaningful stories about how regulation works in practice. It looks beyond legislation to examine how rules are interpreted, implemented, and adapted amid evolving public expectations, political priorities, and technological change. "While technology for regulation is advancing rapidly, the heart of regulation still lies in people and their actions within the broader context," said Kirsty Dusting, Global Vice President, Regulatory Solutions, Objective Corporation. "We aim to tell the story of regulation in motion through the tools, decisions, and pressures that shape it, not just the headlines that occasionally surface it." Rather than focusing on vendors or products, The Modern Regulator explores trends, practices, data, and outcomes that redefine how regulation is delivered and experienced. Its editorial scope includes: Ongoing regulatory news from Australia, New Zealand, and the UK In-depth features on cross-cutting themes and sector-specific developments Coverage of intersections between regulation and digital identity, cybersecurity, automation, AI and more Policy analysis focused on the public aims of regulation and how they are achieved Guest contributions from professionals working in and around the regulatory space "Good regulation is adaptive. It responds not only to technology, but to changing expectations, institutional realities, and new ways of solving problems," said Kirsty. "We want to shine a light on the thinkers and practitioners pushing regulation forward, often in ways that go unnoticed." Behind the publication is a team with decades of combined experience in journalism, technology, public policy, and government. The Modern Regulator was launched to meet a growing need for informed, independent commentary at the intersection of regulation, digital transformation, and public service. Published by Objective Corporation, The Modern Regulator operates with editorial independence and focuses on thoughtful, non-partisan coverage. Subscribe now for regular updates on regulatory developments, trends, and insights Visit the site: View original content to download multimedia: SOURCE Objective
Yahoo
2 hours ago
- Yahoo
Food firms slash salt and sugar by nearly a third
Food firms have cut salt and sugar levels in their products by nearly a third over the past decade, according to a report. But UK manufacturers across the sector are calling for more funding and 'bold action' to help drive further innovation in healthy eating. The Food and Drink Federation (FDF) said research by Kantar Worldpanel showed products made by its members have 31% less salt, 30% less sugar and a quarter fewer calories than they did 10 years ago. The group – whose members make a quarter of all food and drink sold in the UK – said the progress comes after years of investment by the industry, including around £180 million in healthier product innovation in 2024 alone. But the FDF said rising cost and regulation pressures are putting this investment under pressure, with a recent survey of its members showing 41% are planning to scale back spend on this as a result. It wants extra funding support and is urging the Government to take 'bold, co-ordinated action across the whole food system' to help with the shift towards healthier food. 'This includes mandatory reporting on the sales of healthier and less healthy products across manufacturing, retail and hospitality,' the FDF said. 'It also means taking a more consistent approach to health policy across the entire food chain, ensuring consumers have access to the same clear information that helps them to make healthier choices, no matter where they're eating,' it added. As well as funding for research and development and science support to the food sector, it believes the Government should help smaller firms more, with a similar scheme to the Scottish Government's Reformulation for Health programme. Efforts so far by the industry have included changing recipes and portion sizes. Some manufacturers have added extra portions of vegetables, while others have invested in new machinery to make changes to the cooking process and recipe. Karen Betts, chief executive of the FDF, said: 'Companies have made major progress in slashing the calories, salt and sugar in everyday food and drink – making the food people love better for them, alongside hugely expanding the range of healthy options. 'But tackling poor diets and lifestyles is a complex issue and needs a more joined-up approach. 'We're calling on the Government today to work in a more structured partnership with the entire food industry to deliver change.' She added that 'holistic and co-ordinated action will help us truly move the needle on this critical health challenge'. A government spokesperson said: 'As part of this government's Plan for Change, we are committed to achieving our health mission to build an NHS fit for the future, which includes shifting from sickness to prevention. 'We are working closely with the food industry to improve people's diets and reduce levels of obesity and have already restricted junk food advertising on TV and online as well as limiting school children's access to fast food outlets. 'Making healthier choices easier is a major part of creating a food environment that is fairer, with the fewest lives lost to the biggest killers and where everyone lives well for longer.'
